Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 362

1.

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ; RADIANCE 2 Investigators.

Lancet. 2007 Jul 14;370(9582):153-60.

PMID:
17630038
[PubMed - indexed for MEDLINE]
2.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML; RADIANCE 1 Investigators.

N Engl J Med. 2007 Apr 19;356(16):1620-30. Epub 2007 Mar 26.

PMID:
17387131
[PubMed - indexed for MEDLINE]
Free Article
3.

Effect of torcetrapib on the progression of coronary atherosclerosis.

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators.

N Engl J Med. 2007 Mar 29;356(13):1304-16. Epub 2007 Mar 26. Erratum in: N Engl J Med. 2007 Aug 23;357(8):835. Lasala, Gregory P [corrected to Lasala, Gabriel P].

PMID:
17387129
[PubMed - indexed for MEDLINE]
Free Article
4.
5.

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ.

Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum in: Circulation. 2009 Feb 10;119(5):e197.

PMID:
19029469
[PubMed - indexed for MEDLINE]
Free Article
6.

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.

Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF.

Lancet. 2001 Feb 24;357(9256):577-81.

PMID:
11558482
[PubMed - indexed for MEDLINE]
7.

Effects of torcetrapib in patients at high risk for coronary events.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators.

N Engl J Med. 2007 Nov 22;357(21):2109-22. Epub 2007 Nov 5.

PMID:
17984165
[PubMed - indexed for MEDLINE]
Free Article
8.

Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.

Shukla A, Sharma MK, Jain A, Goel PK.

Indian Heart J. 2005 Nov-Dec;57(6):675-80.

PMID:
16521637
[PubMed - indexed for MEDLINE]
9.

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA.

Lancet. 2007 Dec 8;370(9603):1907-14.

PMID:
18068514
[PubMed - indexed for MEDLINE]
10.

Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.

Dogan S, Duivenvoorden R, Grobbee DE, Kastelein JJ, Shear CL, Evans GW, Visseren FL, Bots ML; Radiance 1 and Radiance 2 Study Groups.

Ann Med. 2010 Sep;42(6):447-64. doi: 10.3109/07853890.2010.499132.

PMID:
20645885
[PubMed - indexed for MEDLINE]
11.

Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.

Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J.

Cardiovasc Drugs Ther. 2012 Aug;26(4):349-58. doi: 10.1007/s10557-012-6395-z.

PMID:
22622962
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ.

N Engl J Med. 2004 Apr 8;350(15):1505-15.

PMID:
15071125
[PubMed - indexed for MEDLINE]
Free Article
13.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
[PubMed - indexed for MEDLINE]
14.

Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators.

N Engl J Med. 2008 Apr 3;358(14):1431-43. doi: 10.1056/NEJMoa0800742. Epub 2008 Mar 30. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.

PMID:
18376000
[PubMed - indexed for MEDLINE]
Free Article
15.

Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.

Zareba G.

Drugs Today (Barc). 2006 Feb;42(2):95-102.

PMID:
16541186
[PubMed - indexed for MEDLINE]
16.

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.

Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC.

Am Heart J. 2009 Feb;157(2):352-360.e2. doi: 10.1016/j.ahj.2008.09.022. Epub 2008 Dec 20.

PMID:
19185645
[PubMed - indexed for MEDLINE]
17.
18.
19.

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.

Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.

Clin Ther. 2008 Jun;30(6):1089-101. doi: 10.1016/j.clinthera.2008.05.017.

PMID:
18640465
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk